Our objective was to evaluate a relatively low dose of EC17 (0.1 mg/kg) in a larger group of ovarian cancer patients and to assess feasibility of intraoperative fluorescence imaging in patients with FRα positive breast cancer. The gene discussed is FOLR1; the disease is ovarian carcinoma.